Connection
Paul Bunn to Prostatic Neoplasms
This is a "connection" page, showing publications Paul Bunn has written about Prostatic Neoplasms.
|
|
Connection Strength |
|
 |
|
 |
|
0.099 |
|
|
|
-
Stewart JM, Chan DC, Simkeviciene V, Bunn PA, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L. Bradykinin antagonists as new drugs for prostate cancer. Int Immunopharmacol. 2002 Dec; 2(13-14):1781-6.
Score: 0.032
-
Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100.
Score: 0.028
-
Sun W, Bunn P, Jin C, Little P, Zhabotynsky V, Perou CM, Hayes DN, Chen M, Lin DY. The association between copy number aberration, DNA methylation and gene expression in tumor samples. Nucleic Acids Res. 2018 04 06; 46(6):3009-3018.
Score: 0.023
-
Seifter EJ, Bunn PA, Cohen MH, Makuch RW, Dunnick NR, Javadpour N, Bensimon H, Eddy JL, Minna JD, Ihde DC. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol. 1986 Sep; 4(9):1365-73.
Score: 0.010
-
Ihde DC, Bunn PA, Cohen MH, Dunnick NR, Eddy JL, Minna JD. Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression. Cancer. 1980 Mar 15; 45(6):1300-10.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|